




General description

Plazomicin is a next-generation aminoglycoside ("neoglycoside") used in the treatment of multi-drug resistant infections caused by carbapenem resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii.

INN	Plazomicin
Medicine type	Chemical agent
Antibiotic groups	 RESERVE
EML status history	First added in 2019 (TRS 1021) for Carbapenem resistant Enterobacteriaceae Added in 2019 (TRS 1021) for Carbapenem-resistant Pseudomonas aeruginosa Added in 2019 (TRS 1021) for Carbapenem resistant Acinetobacter baumannii
Therapeutic equivalent for	
Wikipedia	Plazomicin 
DrugBank	Plazomicin 

Recommendations

Section Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL (Injection)

Indications

Carbapenem resistant Enterobacteriaceae

Carbapenem-resistant Pseudomonas aeruginosa

Carbapenem resistant Acinetobacter baumannii

